Ocugen, Inc. (OCGN)

1.2500 +0.0100 (+0.81%) At close: 04:00PM EDT

Ocugen, Inc.

11 Great Valley Parkway
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 65

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Shankar Musunuri M.B.A., Ph.D.	Co-Founder, CEO & Chairman	1.2M	1.26M	1964
Dr. Uday B. Kompella Ph.D.	Co-founder & Independent Director	56.72k	N/A	1967
Mr. Michael Breininger CPA, M.B.A.	Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller	N/A	N/A	1982
Dr. Arun Upadhyay Ph.D.	Chief Scientific Officer and Head of Research & Development	N/A	N/A	1983
John Kouch J.D.	General Counsel	N/A	N/A	N/A
Ms. Tiffany J. Hamilton M.B.A.	Head of Corporate Communications	N/A	N/A	N/A
Dr. Durgaprasad Annavajjula Ph.D.	VP, Head of Program Management & Chief of Staff	N/A	N/A	N/A
Mr. Michael Shine M.B.A.	Senior Vice President of Commercial	N/A	N/A	N/A
Ms. Jyothy Pillai M.S.	Head of Regulatory & Quality	N/A	N/A	N/A
Dr. Huma Qamar CMI, M.D., M.P.H.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Corporate governance

Ocugen, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.